Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. Co.'s pipeline is comprised of four programs being developed initially for the treatment of I&I indications. Co.'s two primary programs, APG777 and APG808, which Co. is initially developing for the treatment of AD and COPD, respectively. Moreover, Co. is evaluating APG777 in additional I&I indications, including asthma, areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and prurigo nodularis. We show 3 historical shares outstanding datapoints in our coverage of APGE's shares outstanding history.
Understanding the changing numbers of APGE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like APGE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching APGE by allowing them to research APGE shares outstanding history
as well as any other stock in our coverage universe. |
Free APGE Email Alerts:
Video: Shares Outstanding Importance
